[go: up one dir, main page]

AP887A - Novel 5-0-deoaminyl 6-0-methyl erythronolide a derivatives method for preparing same application thereof for preparing biologically active products. - Google Patents

Novel 5-0-deoaminyl 6-0-methyl erythronolide a derivatives method for preparing same application thereof for preparing biologically active products. Download PDF

Info

Publication number
AP887A
AP887A APAP/P/1998/001210A AP9801210A AP887A AP 887 A AP887 A AP 887A AP 9801210 A AP9801210 A AP 9801210A AP 887 A AP887 A AP 887A
Authority
AP
ARIPO
Prior art keywords
formula
radical
compound
methyl
carbon atoms
Prior art date
Application number
APAP/P/1998/001210A
Other versions
AP9801210A0 (en
Inventor
Alain Bonnet
Michel Delthil
Alain Mazurie
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9482423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP887(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AP9801210A0 publication Critical patent/AP9801210A0/en
Application granted granted Critical
Publication of AP887A publication Critical patent/AP887A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A subject of the invention is the compounds of formula (I): in which OR-| , OR2 and OR3 represent hydroxyl radicals blocked in the form of easily cleavable radicals. The compounds of formula (I) can be used to prepare antibiotic products.

Description

New derivatives of 5-O-desosaminyl 6-O-methyl erythronolide A, their preparation process and their use for the preparation of bioloqically-active products.
The present invention relates to new derivatives of 5-Odesosaminyl 6-O-methyl erythronolide A, their preparation process and their use for the preparation of biologicallyactive products.
A subject of the invention is the compounds of formula (I) :
(I)
AP/P/ 98/01210
(..·· in which:
either Rq represents an alkyl radical containing up to 8 carbon atoms substituted by one or more alkyl radicals containing up to 8 carbon atoms, or by one or more aryl radicals containing up to 14 carbon atoms, or Rq represents an aryl radical containing up to 14 carbon atoms, optionally substituted by one or more alkyl, alkenyl or alkynyl radicals containing up to 8 carbon atoms, alkoxy or alkylthio radicals containing up to 8 carbon atoms, nitro, CF3 radicals or by one or more halogen atoms, or Rq represents a radical:
Rb·
Ra
I
-CRc
APO 0 0 8 8 7
- 2 in which Ra represents an alkyl or alkoxy radical containing up to 8 carbon atoms,
Rb represents an alkyl radical containing up to 8 carbon atoms, optionally substituted by a heteroatom,
Rc represents a hydrogen atom or an alkyl radical containing up to 8 carbon atoms,
R2 and R3, identical or different, represent a trialkylsilyl radical in which the alkyl radical contains up to 8 carbon atoms,
R' a
I a -C--R'b radical, a C- Rd radical,
R'c ΰ in which R'a, R'b, R'c and Rd represent an alkyl radical containing up to 8 carbon atoms, or an aralkyl radical containing up to 8 carbon atoms, optionally substituted by one or or more of the substituents indicated above for Rq.
/In the definition of compounds of the invention:
- the alkyl, alkenyl or alkynyl radical is preferably one of the following radicals: methyl, ethyl, propyl, isopropyl, nbutyl, isobutyl, terbutyl, decyl or dodecyl, vinyl, allyl, ethynyl, propynyl, cyclobutyl, cyclopentyl or cyclohexyl,
- the halogen is preferably fluorine or chlorine, or bromine,
- the aryl radical is preferably the phenyl radical, or a naphthyl radical,
- the aralkyl radical is preferably a (C5H5)-(CH2)a radical, a being an integer comprised between 1 and 6, for example the number 1, 2, 3 or 4; the aralkyl radical can be for example, an optionally substituted benzyl radical or a trityl radical,
- the alkyloxy radical is preferably one of the following radicals: methoxy, ethoxy, propyloxy isopropyloxy, nbutyloxy, isobutyloxy, tert-butyloxy, n-pentyloxy, isopentyloxy, sec-pentyloxy, tert-pentyloxy, neopentyloxy, nhexyloxy, sec-hexyloxy, tert-hexyloxy,
- the corresponding alkylthio radical can be used by taking the same values and replacing the oxygen atom with a sulphur, atom, for example: methylthio, ethylthio. Furthermore, the sulphur atom -can be oxidized, for example: methylsulphinyl,
AP/P/ 98/01210
APO00887
- 3 methyisulphonyl.
The compounds of the invention can be used for the preparation of compounds of formula (VI):
in which Z represents a hydrogen atom or a protective group such as the remainder of a carboxylic acid containing up to 8 carbon atoms, a trialkylsilyl or terbutyl radical. The compounds of formula (VI) are described and claimed in the , *
European Patent Application 0,487,411, as intermediates useful in particular for the preparation of antibiotic products.
A more particular subject of the invention is the compounds of formula (I) in which R-] represents a
Ra
Rb-0-CRc radical in which Ra, Rb and Rc retain the same meaning as previously and in particular those in which Ra, Rb and Rc represent a methyl radical as well as the compounds of formula (I) in which R2 and R3 both represent a trialkylsilyl
AP/P/ 9 8/01210
APO 00 8 8 7
- 4 radical and in particular those in which F?2 and R3 represent a trimethylsilyl radical.
A more particular subject of the invention is the compound of formula (I) whose preparation is given hereafter in the experimental part.
A subject of the invention is also a preparation process for the compounds of formula (I) as defined previously, characterized in that the compound of formula (II):
is subjected to the action of an agent blocking the oxime in position 9, in order to obtain a compound of formula (III):
H
AP/P/ 9 8/01210 in which R-| retains its previous meaning, which is subjected to the action of an agent blocking the hydroxyl in position 3 and/or in position 2' in order to obtain the compound of formula (IV):
ΑΡΟ 00687
- 5 \~ϊ·
in which R-j , R2 and R3 retain their previous meaning, which is subjected to the action of a methylation agent of the hydroxyl in position 6, in order to obtain the corresponding compound of formula (I).
The compound of formula (II) used as starting product is a known product described by Le Mahieu et al. in J. Med.
Chem. 1_7 (9) 953-956 (1974).
In a preferred implementation of the process of the invention:
- the oxime in position 9 is protected in the ketal or thioketal form,
- the 3-OH and 2'-OH groups are blocked by trimethylsilyl groups,
- the methylation is carried out using methyl iodide in the presence of a base for example potash, soda, a hydride such as sodium hydride, an alkali metal terbutylate such as for example potassium terbutylate or also in the presence of 1,5diazabicyclo [4,3,0] non-5-ene or 1,8-diazabicyclo [5,4,0] undec-7-ene.
AP/P/ 98/01210
APO00887
- 6 A subject of the invention is also as new chemical products the products of formula (III) and formula (IV) obtained during the implementation of the process of the invention. A more particular subject of the invention is the products of formulae (III) and (IV) whose preparation is given hereafter in the experimental part.
A subject of the invention is also the use of the compounds of formula (I), characterized in that the compound of formula (I) is subject to the following stages:
- release of the oxime in position 9,
- release of the hydroxyl in position 3 and 2',
- protection of the hydroxyl in position 2'.
A particular subject of the invention is the use characterized in that a compound of formula (I) is subjected to the action of formic acid in the presence of sodium bisulphite or sodium metabisulphite in order to directly obtain the compound of formula (V):
AP/P/ 9 8/01210 which is subjected to the action of a protection agent of the hydroxyl in position 2' in order to obtain the compound of formula (VI):
AP Ο Ο Ο 8 8 7
- Ί -
in which Ζ represents a protective group such as the remainder of a carboxylic acid containing up to 8 carbon atoms, or a trialkylsilyl, terbutyl or triphenylmethyl radical.
J
In addition a subject of the invention is the use characterized in that a compound of formula (I) is subjected to the action of an agent releasing the hydroxyl in position 3 and in position 2' in order to obtain the compound of formula (VII):
AP/P/ 98/01210
H in which R-j retains its previous meaning, which is subjected to the action of a protection agent of the OH group in position 2' in order to obtain the compound of formula (VIII):
ΑΡουυβ87
(VIII)
J in which R] retains its previous meaning and Z represents a 20 protective group as defined previously, which is subjected to the action of an agent releasing the 9-oxo group in order to obtain the corresponding compound of formula (VI):
AP/P/ 98/01210 in which Z reutains its previous meaning.
AP Ο ϋ Ο β 8 7
- 9 The following examples illustrate the invention without however limiting it.
EXAMPLE 1: 9—O—(1—methoxy—1—methylethyl) oxime of 3—0— de(2,6—dideoxy—3—C—methyl—3—0—methyl—alpha—L—ribo— hexopyranosyl)-2',3-0—bis (trimethylsilyl) 6—0—methyl erythromycin.
Stage A: 9-0-(1-methoxy-1-methylethyl) oxime of 3-0-de(2,6dideoxy-3-C-methyl-3-0-methyl-alpha-L-ribo-hexopyranosyl) erythromycin
8.14 g of 9-oxime of 3-0-de(2,6-dideoxy-3-C-methyl-3-0methyl-alpha-L-ribo-hexopyranosyl) erythromycin, 81.5 ml of methylene chloride, 9.65 ml of 2-methoxy propene and 2.44 g '/J of 98% pyridinium hydrochloride are agitated for half an hour at ambient temperature. 80 ml of a saturated solution of
NaHC03 added, followed by agitation for 3 minutes. The organic phase is decanted and washed with 50 ml of salt water. The aqueous phases are reextracted with 50 ml of CH2CI2. The organic phase is dried over Na2SO4 and the solvent is evaporated off under reduced pressure. 9 g of desired product is recovered.
Yield: 98.5%.
Analytical results:
/ NMR (CDCI3, 300 MHz)
0.84 (t): CH3-CH2; 1.07 (d)-1.09 (d)-1.23 (d)-1.26 (d)x2: the . 3 25 CH3-CH's; 2.25 (s): N(Me)2; 2.48 (m): H'3; 2.64 (dq): H2;
2.72 (bq): H10; 3.22 (s): OMe; -3.25: H'2; 3.51 (d): H5; 3.58 (bd.): H3; 3.68 (bs): Ηη η; -3.50 (m): H'5; -3.62 (m): H8 >
E; 4.41 (d): H'-j; 5.23 (dd): ΗΊ3; 2.36-4.48-3.58: mobile H's.
Stage B: 9-0-(1-methoxy-1-methylethyl) oxime of 3-0-de(2,630 dideoxy-3-C-methyl-3-0-methyl-alpha-L-ribo-hexopyranosyl)2' , 3-O-bis(trimethylsilyl) erythromycin
A mixture of 6.62 g of the product prepared in the preceding stage, 66 ml of CH2CI21 2.95 ml of Ntrimethylsilyl imidazole and 1.7 ml of trimethylsilyl chloride is agitated for 45 minutes at ambient temperature.
ml of a saturated solution of NaHC03 is added. The organic phase is decanted and washed with 30 ml of salt water. The aqueous phases are reextracted with 40 ml of
AP/P/ 98/01210
APOϋ0887
- 10 CH2CI2· The organic phase is dried over Na2SC>4 and the solvent is evaporated off under reduced pressure. 7.5 g of desired product is recovered.
Yield: 92.9%.
Analytical results:
NMR (CDCI3, 300 Mhz)
0.12-0.16 the OTMS's; 0.84 (t): CH3-CH7; 1.16 (x2)-1.38-1.451 .47-1.00-1.25: the CH3-CH's; 2.23 (s): N(Me)2,* 2.47 (m):
H'3; 2.71 (m) : H2 and H-|q; 3.16 (dd): H'2; 3.22 (s): OMe;
3.45 (m): H'5; 3.58 (d): H5; 3.66: H8 ---> E; 3.66 (s): Hn ;
3.98 (bd): H3; 4.2 (dd): H'-|; 5.14 (dd): H13; 1.90 (s)-3.104.44: OH.
' Stage C: 9-O-(1-methoxy-1-methylethyl) oxime of 3-O-de(2,6dideoxy-3-C-methyl-3-0-methyl-alpha-L—ribo-hexopyranosyl)15 2',3-O-bis(trimethylsilyl) 6-O-methyl erythromycin
1.24 g of the product prepared in the preceding stage,
8.7 ml of a dimethyl sulphoxide/tetrahydrofuran mixture 1/1, 190 jal of methyl iodide and 161 mg of 90% powdered potash are agitated for 2 hours at ambient temperature. 10 ml of AcOEt and 10 ml of a 0.5 M monosodium phosphate solution are added. After decanting and reextraction with AcOEt, the organic phase is washed with 5 ml of water, dried over Na2SO4 and the filtrate is concentrated under reduced pressure. 1.2 g of the desired product is obtained.
» 25 Yield: 95%.
Analytical results:
NMR (CDCI3, 300 MHz)
Possible structure, the SiMe3's are located at 0.11 and 0.20; 0.84^ (t): CH3-CH2; 0.95 (d)-0.97 (d)-1.14 (d)-1 .17 (d) x 2: the CH3-CH's; 1.18-1.35-1.40-1.48 the CH3-CH's; 2.22 (s): N(Me)2; 2.46 (m): H'3; 2.61 (bq) : H-|0; 2.72 (dg) : H2; 3.01 (s): OMe; 3.13 (dd): H'5; 3.22 (s): OMe chain; 3.45 (m):
H'5; -3.70: H8 ---> E; -3.68 (m): 2H (H3, H5); 3.79 (bs)
1H---> Hn; 4.24 (d): Η'ί; 5.15 (dd): H13; 3.29 (s) and 4.52 the OH's.
Use 1 : 2'—O—acetyl 3—O—de(2,6-dideoxy 3-C—methyl 3—O—methyl alpha—L—ribo—hexopyranosyl) 6-O-methyl erythromycin
Stage A: 3—O-de(2,6-dideoxy 3-C-methyl 3-O-methyl alpha—
01210/86 /d/dV
APO 0 0 887
- 11 ribo-hexopyranosyl) 6-O-methyl erythromycin
A mixture of 513 mg of the product of Example 1, 5 ml of
EtOH/water 1/1, 425 mg of sodium bisulphite and 115 pi of formic acid is agitated under reflux for half an hour. After cooling the mixture down to ambient temperature, 5 ml of a saturated solution of NaHCC>3 is added. The mixture is agitated for 5 minutes then extraction is carried out twice with AcOEt. The extraction phases are washed with 5 ml of a saturated solution of NaCl. The organic phase is dried over
Na2SC>4 and the solvent is evaporated off under vacuum.
180 mg of desired product is obtained, after chromatography k on silica with AcOEt 95/MeOH 3/TEA 2 as eluant.
Yield: 48%.
Analytical results:
NMR (CDCI3, 250 MHz)
Spectrum identical to the data in the literature 5.17 (d): H13; 4.38 (d): H'1; 3.93 (bs): mobile H; 3.85 (s): Hqη; 3.68 (s): H5; 3.54 to 3.62 (m): H3, H's: 3.24 (m): H'2; 2.987 (s): OMe; 2.25 (s): N(Me)2; 1.37-1.31-1.27-1.25-1.2120 1.18-1.14-1.11: theCH3-CH's; 0.83 (t): CH3-CH2·
Stage B: 2'-O-acetyl 3-O-de(2,6-dideoxy 3-C-methyl 3-0methyl alpha-L-ribo-hexopyranosyl) 6-O-methyl erythromycin 'The product of the preceding stage is subjected to the action of acetic anhydride and the desired product is 1 25 obtained.
Use 2: 2'—O-acetyl 3-O-de(2,6-dideoxy 3-C-methyl 3-O-methyl alpha-L-ribo-hexopyranosyl) 6-O-methyl erythromycin Stage A: 9-0-(2-methoxy 2-methylethyl) oxime of 3-O-de(2,6dideoxy 3qC-methyl 3-O-methyl alpha-L-ribo-hexopyranosyl) 630 0-methyl erythromycin
8.25 ml of 1M tetrabutyl ammonium fluoride in tetrahydrofuran is added rapidly at ambient temperature to a mixture of 2.75 g of the product of Example 1 and 5.5 ml of tetrahydrofuran, then agitation is carried out for 45 minutes. Next a mixture of 15 ml of ethyl acetate and 15 ml of ice-cooled water are added. After decanting, the organic phase is reextracted with 3 ml of water. 0.82 ml of concentrated ammonium hydroxide is added to the aqueous
AP/P/ 9 8/01210 phase? The aqueous phase is extracted with ethyl acetate.
The organic phase is washed with 3 ml of a solution of water saturated with sodium chloride then it is dried over sodium sulphate and the solvent is evaporated off under reduced pressure. 2.17 g of desired product is recovered.
Yield: 95.7%
Analytical results:
NMR (CDCI3, 300 MHz)
AP Ο ϋ Ο 8 8 7
0.84 (t): CH3-CH2; 0.97 (d) — 1.10 (cl)—1 .18 (d)-1.24 (d)-1. 26
(d) the CH3-CH's; 1.20-1 .40 (x 2) -1.48 the CH3-C's; 2.26 (s):
N(Me)2; 2.13 (bq): H4; 2 .48 (m) : H'3; ~2.66: Hqq and H3; 2.98
(s): OMe in position 6; 3.22 (s): OMe chain; ~3.26: H'2;
~3.54: H3 and H'5; 3.68 (s) — 3.83 (d): H5 and Hq-| ; ~3.73 (m)
•««’Μ»,
I :.. ζ*·
Hg---> E; 4.38 (d): H'-|; 5.23 (dd) : H-|3.
Stage B: 9-0-(2-methoxy 2-methylethyl) oxime of 2'-O-acetyl 3-O-de(2,6-dideoxy 3-C-methyl 3-O-methyl alpha-ribo-Lhexopyranosyl) 6-O-methyl erythromycin
A mixture of 2.17 g of the product prepared in the preceding stage, 22 ml of CH2CI2 and 390 pi of acetic anhydride is agitated for one hour 30 minutes at ambient temperature. 22 ml of a saturated solution of sodium bicarbonate is added. The organic phase is washed with 10 ml of salt water. The aqueous phases are reextracted with CH2CI2. The organic phase is dried over sodium sulphate, then the solvent is evaporated off under reduced pressure.
The residue obtained is taken up in 4.25 ml of isopropyl ether then 14.9 ml of heptane. After agitation for 5 minutes, the precipitate is separated off then washed with heptane. ..After drying 1.72 g of desired product (colourless crystals) is recovered, M.p. = 200°C. Yield: 74.7%. Analytical results:
NMR (CDCI3, 300 MHz)
0.83 (t): CH3-CH2; 0.92 (d)-0.97 (d)-1.17 (d)-1.28 (d)-1.30 (d) the CH3-CH's; 1.18-1.29-1.40-1.47 the CH3-C's; 2.06 (s):
OAc; 2.26 (s): N(Me)2; 2.59 (bq): H10; 2.69 (m): H'3 and H2; 2.95 (s): OMe in position 6; 3.22 (s): OMe chain; ~3.47: H3; Hg and H'5; 3.73 (d) : H5 and 3.79 (bs): H-]-| ; 4.60 (d): Η' Ί ; 4.77 (dd): H'.2; 5.23 (dd): Hq3; 1.72 (d)-3.32- 4.63: mobile
AP/P/ 9 8/01210
ί.
ΑΡθ ο 0 887
H'S.
Stage C: 2'-O-acetyl 3-O-de(2,6-dideoxy 3-C-methyl 3-0methyl alpha-L-ribo-hexopyranosyl) 6-O-methyl erythromycin
A mixture of 180 mg of the product prepared in the 5 preceding stage, 1.8 ml of ethanol/water 1/1, 23 pi of 98% formic acid and 180 mg of sodium bisulphite is agitated under reflux for 3 hours 30 minutes. The mixture is cooled down to ambient temperature and 1.8 ml of a saturated solution of sodium bicarbonate is added. After agitation for 3 minutes, extraction is carried out twice with CH2CI2· The organic phase is washed with 2 ml of a saturated aqueous solution of NaCl. The organic phase is dried over sodium sulphate and the solvent is evaporated off under reduced pressure. After purification of the residue by chromatography on silica, eluting with ethyl acetate with 2% tetrahydrofuran, 43 mg of desired product is recovered. Yield: 27%.
Analytical results:
IR: / -OH ~3626 cm-1 (Max)
>=O 3500 cm-1 1735 cm-1
1689 cm-1.
AP/P/ 9 8/01210

Claims (12)

1) The compounds of formula (I):
in which:
either R-] represents an alkyl radical containing up to 8 carbpn atoms substituted by one or more alkyl radicals containing up to 8 carbon atoms, or by one or more aryl
20 radicals containing up to 14 carbon atoms, or R-] represents an aryl radical containing up to 14 carbon atoms, optionally substituted by one or more alkyl, alkenyl * or alkynyl radicals containing up to 8 carbon atoms, alkoxy or alkylthio radicals containing up to 8 carbon atoms, nitro,
25 CF3 radicals or by one or more halogen atoms, or Rq represents a radical:
Ra
Rb-0-C30 rc
AP/P/ 9 8/01210 in which Ra represents an alkyl or alkoxy radical containing up to 8 carbon atoms,
Rb represents an alkyl radical containing up to 8 carbon 35 atoms, optionally substituted by a heteroatom,
Rc represents a hydrogen atom or an alkyl radical containing up to 8 carbon atoms,
R2 and R3, identical or different, represent a trialkylsilyl
APO00887
radical in which the alkyl atoms, a - R'a -R'b radical, j 5 R'c
a C-Rd radical,
O radical contains up to 8 carbon in which R'a, R'b, R'c and Rd represent an alkyl radical containing up to 8 carbon atoms, or an aralkyl radical containing up to 8 carbon atoms, optionally substituted by one or or more of the substituents indicated above for Rq.
2) The compounds of formula (I) as defined in claim 1 in which Rq represents a
Ra 15 I
Rb-0-CRc
20 radical in which Ra, Rb and Rc retain the same meaning as in claim 1.
3) The compounds of formula (I) as defined in claim 2, in which Ra, Rb and Rc represent a methyl radical.
4) The compounds of formula (I) as defined in one of claims \ ' 25 1 to 3, in which R2 and R3 both represent a trialkylsilyl radical.
5) , The compounds of formula (I) as defined in claim 4, in which R2 and R3 represent a trimethylsilyl radical.
6) The compound of formula (I) defined in claim 1 whose 30 name follows:
9-0-(2-methoxy-2-methylethyl) oxime of 3-O-de(2,6-dideoxy-3C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)-2'0,3-O-bis(trimethylsilyl)-6-O-methyl erythromycin.
7) Preparation process for the compounds of formula (I) as 35 defined in any one of claims 1 to 6, characterized in that the compound of formula (II):
AP/P/ 9 8/01210
APO00887
- 16 ^.0 Η is subjected to the action of an agent blocking the oxime in position 9, in order to obtain a compound of formula (III):
AP/P/ 98/01210 in which R-| retains its previous meaning, which is subjected to the action of an agent blocking the hydroxyl in position 3 and in position 2' in order to obtain the compound of formula (IV):
APOU0887
- 17 10
15 in which Ri, and R3 retain their previous meaning, which is subjected to the action of a methylation agent of the hydroxyl in position 6, in order to obtain the corresponding compound of formula (I).
8) Preparation process according to claim 7, characterized 20 in that the methylation of the compound of formula (IV) is carried out using methyl iodide in the presence of a base.
9) As new chemical products, the compounds of formulae * (III) and (IV) as defined in claim 7.
10) As chemical products defined in claim 9, the following 25 products:
9-0-(2-methoxy-2-methylethy1) oxime of 3-O-de(2,6-dideoxy-3C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl) erythromycin, 9-0-(2-methoxy-2-methylethyl) oxime of 3-0-de(2,6-dideoxy-3C-me thy l-3--0-me thy 1-alpha-L-r ibo-hexopyranosy 1)-2'0, 3-030 bis (trimethylsilyl) erythromycin.
11) Use of the compounds of formula (I) as defined in any one of claims 1 to 5, characterized in that the compound of formula (I) is subjected to the following stages:
- release of the oxime in position 9,
35 - release of the hydroxyl in positions 3 and 2',
- protection of the hydroxyl in position 2' .
12) Use according to claim 11, characterized in that a compound of formula (I) is subjected to the action of formic
AP/P/ 9 8/01210
APUU0887
- 18 acid in the presence of sodium bisulphite or sodium metabisulphite, in order to directly obtain the compound formula (V):
of
AP/P/ 9 8/01210 which is subjected to the action of a protection agent of the hydroxyl in position 2' in order to obtain the compound of formula (VI):
0 z k
AP000887
- 19 in which Z represents a protective group such as the remainder of a carboxylic acid containing up to 8 carbon atoms, or a trialkylsilyl, terbutyl or triphenylmethyl radical.
5 13) Use according to claim 11, characterized in that a compound of formula (I) is subjected to the action of an agent releasing the hydroxyl in position 3 and in position 2' in order to obtain the compound of formula (VII):
;r.rj ’iie?**
AP/P/ 9 8/01210 in which R·} retains its previous meaning, which is subjected to the action of a protection agent of the OH group in position 2' in order to obtain the compound of formula (VIII) :
0 z k:
APOVO 887
- 20 L .·£·£ in which R-j retains its previous meaning and Z represents a protective group as defined previously, which is subjected to the action of an agent releasing the 9-oxo group in order to obtain the corresponding compound of formula (VI):
20 in which Z retains its previous meaning.
APAP/P/1998/001210A 1995-09-11 1996-09-10 Novel 5-0-deoaminyl 6-0-methyl erythronolide a derivatives method for preparing same application thereof for preparing biologically active products. AP887A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9510601A FR2738571B1 (en) 1995-09-11 1995-09-11 NOVEL DERIVATIVES OF 5-0-DESOSAMINYL 6-0-METHYL- ERYTHRONOLIDE A, THEIR PREPARATION PROCESS AND THEIR APPLICATION TO THE PREPARATION OF BIOLOGICALLY ACTIVE PRODUCTS
PCT/FR1996/001384 WO1997010251A1 (en) 1995-09-11 1996-09-10 Novel 5-o-deoaminyl 6-o-methyl erythronolide a derivatives, method for preparing same and application thereof for preparing biologically active products

Publications (2)

Publication Number Publication Date
AP9801210A0 AP9801210A0 (en) 1998-03-31
AP887A true AP887A (en) 2000-11-10

Family

ID=9482423

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1998/001210A AP887A (en) 1995-09-11 1996-09-10 Novel 5-0-deoaminyl 6-0-methyl erythronolide a derivatives method for preparing same application thereof for preparing biologically active products.

Country Status (34)

Country Link
US (1) US5969161A (en)
EP (1) EP0854880B1 (en)
JP (1) JP4332218B2 (en)
KR (1) KR100457755B1 (en)
CN (2) CN1070498C (en)
AP (1) AP887A (en)
AR (1) AR004195A1 (en)
AT (1) ATE266035T1 (en)
AU (1) AU708811B2 (en)
BG (1) BG63822B1 (en)
BR (1) BR9610503A (en)
CA (1) CA2228670C (en)
CZ (3) CZ294866B6 (en)
DE (1) DE69632405T2 (en)
DK (1) DK0854880T3 (en)
EA (1) EA000575B1 (en)
EE (1) EE03774B1 (en)
ES (1) ES2219698T3 (en)
FR (1) FR2738571B1 (en)
GE (1) GEP20022838B (en)
HK (1) HK1041489B (en)
HU (1) HU227565B1 (en)
IL (1) IL123550A (en)
MX (1) MX9801859A (en)
NO (2) NO312678B1 (en)
PL (1) PL183652B1 (en)
PT (1) PT854880E (en)
RO (1) RO120137B1 (en)
SI (1) SI0854880T1 (en)
SK (3) SK285995B6 (en)
TR (1) TR199800438T1 (en)
UA (1) UA53628C2 (en)
WO (1) WO1997010251A1 (en)
ZA (1) ZA966837B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263972C (en) * 1996-09-04 2008-01-29 Abbott Laboratories 6-o-substituted ketolides having antibacterial activity
UA51730C2 (en) * 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-0-substituted ketolides having antibacterial activity
US6034069A (en) * 1997-09-30 2000-03-07 Abbott Laboratories 3-'N-modified 6-O-substituted erythromycin ketolide derivatives having antibacterial activity
US6124269A (en) * 1997-10-29 2000-09-26 Abbott Laboratories 2-Halo-6-O-substituted ketolide derivatives
US6046171A (en) * 1997-10-29 2000-04-04 Abbott Laboratories 6,11-bridged erythromycin derivatives
US6054435A (en) * 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
EP1483277A4 (en) * 2002-02-15 2007-10-03 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US7910558B2 (en) * 2002-05-13 2011-03-22 Enanta Pharmaceuticals, Inc. Bridged macrocyclic compounds and processes for the preparation thereof
US7135573B2 (en) * 2002-05-13 2006-11-14 Enanta Pharmaceuticals, Inc. Processes for the preparation of O-(6-Pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine
US6764998B1 (en) 2003-06-18 2004-07-20 Enanta Pharmaceuticals, Inc. 6,11-4C-bicyclic 9a-azalide derivatives
US6878691B2 (en) * 2002-05-13 2005-04-12 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
US6753318B1 (en) 2002-07-25 2004-06-22 Enanta Pharmaceuticals, Inc. 6,11-4-carbon bridged erythromycin derivatives
WO2005070918A1 (en) * 2002-05-13 2005-08-04 Enanta Pharmaceuticals, Inc. Process for the preparation of t-11 bicyclic erythromycin derivatives
US7273853B2 (en) * 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
US7064110B2 (en) * 2002-05-13 2006-06-20 Enanta Pharmaceuticals, Inc. 6-11 bicycle ketolide derivatives
US6841664B2 (en) 2002-07-25 2005-01-11 Enanra Pharmaceuticals, Inc. 6,11-4-carbon bridged ketolides
US7129221B2 (en) * 2002-05-13 2006-10-31 Enanta Pharmaceuticals, Inc. 6,11-bicyclic erythromycin derivatives
ITMI20021726A1 (en) * 2002-08-01 2004-02-02 Zambon Spa MACROLIDS WITH ANTI-INFLAMMATORY ACTIVITY.
US6645941B1 (en) 2003-03-26 2003-11-11 Enanta Pharmaceuticals, Inc. 6,11-3C-bicyclic 9a-azalide derivatives
US7276487B2 (en) * 2003-09-23 2007-10-02 Enanta Pharmaceuticals, Inc. 9a, 11-3C-bicyclic 9a-azalide derivatives
WO2005067564A2 (en) * 2004-01-07 2005-07-28 Enanta Pharmaceuticals, Inc. 6-11 bicyclic erythromycin derivatives
WO2005070113A2 (en) * 2004-01-09 2005-08-04 Enanta Pharmaceuticals, Inc. 9n-substituted 6-11 bicyclic erythromycin derivatives
US7229972B2 (en) 2004-12-07 2007-06-12 Enanta Pharmaceuticals, Inc. 3,6-Bicyclolides
US7419962B2 (en) 2004-12-07 2008-09-02 Enanta Pharmaceuticals, Inc. 3,6-bicyclolides
US7291602B2 (en) 2004-12-13 2007-11-06 Enanta Pharmaceuticals, Inc. 11,12-lactone bicyclolides
WO2006065743A2 (en) 2004-12-13 2006-06-22 Enanta Pharmaceuticals, Inc. Tetracylic bicyclolides
US7384922B2 (en) * 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
JP2009502838A (en) * 2005-07-26 2009-01-29 メルクレ，ゲーエムベーハー Macrolide conjugates of pyrrolidine and indolizine compounds
US8354383B2 (en) * 2007-09-17 2013-01-15 Enanta Pharmaceuticals, Inc. 6,11-bridged biaryl macrolides
US8273720B2 (en) * 2007-09-17 2012-09-25 Enanta Pharmaceuticals, Inc. 6,11-bicyclolides: bridged biaryl macrolide derivatives
MX2010002932A (en) * 2007-09-17 2010-05-27 Enanta Pharm Inc 6, 11-bridged biaryl macrolides.
CN103232501A (en) * 2013-04-11 2013-08-07 宜昌东阳光药业股份有限公司 A preparation process for compounds of azithromycin or azithromycin intermediates with cladinose removed

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272110A2 (en) * 1986-12-17 1988-06-22 Taisho Pharmaceutical Co. Ltd Erythromycin a derivatives and method for the preparation of the same
EP0619319A1 (en) * 1991-12-27 1994-10-12 Taisho Pharmaceutical Co. Ltd 5-0-desosaminylerythronolide derivative

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0272110A2 (en) * 1986-12-17 1988-06-22 Taisho Pharmaceutical Co. Ltd Erythromycin a derivatives and method for the preparation of the same
EP0619319A1 (en) * 1991-12-27 1994-10-12 Taisho Pharmaceutical Co. Ltd 5-0-desosaminylerythronolide derivative
EP0619320A1 (en) * 1991-12-27 1994-10-12 Taisho Pharmaceutical Co. Ltd 5-o-desosaminylerythronolide derivative

Also Published As

Publication number Publication date
SK29498A3 (en) 1998-12-02
IL123550A (en) 2002-09-12
AR004195A1 (en) 1998-11-04
NO981053D0 (en) 1998-03-10
GEP20022838B (en) 2002-11-25
EE03774B1 (en) 2002-06-17
DE69632405T2 (en) 2005-05-19
CN1319602A (en) 2001-10-31
NO20021111D0 (en) 2002-03-06
EA000575B1 (en) 1999-12-29
SK285995B6 (en) 2008-01-07
EE9800065A (en) 1998-08-17
HU227565B1 (en) 2011-08-29
AU6991096A (en) 1997-04-01
CA2228670A1 (en) 1997-03-20
NO20021111L (en) 1998-03-10
CN1201462A (en) 1998-12-09
BR9610503A (en) 1999-07-06
TR199800438T1 (en) 1998-05-21
AP9801210A0 (en) 1998-03-31
NO315048B1 (en) 2003-06-30
DE69632405D1 (en) 2004-06-09
CN1237069C (en) 2006-01-18
JPH11512416A (en) 1999-10-26
NO981053L (en) 1998-03-10
ES2219698T3 (en) 2004-12-01
SK283690B6 (en) 2003-12-02
CZ294866B6 (en) 2005-04-13
BG102312A (en) 1998-09-30
CZ294865B6 (en) 2005-04-13
PL326274A1 (en) 1998-08-31
CZ71798A3 (en) 1998-07-15
JP4332218B2 (en) 2009-09-16
HK1016187A1 (en) 1999-10-29
FR2738571B1 (en) 1997-10-17
KR19990044543A (en) 1999-06-25
MX9801859A (en) 1998-11-30
DK0854880T3 (en) 2004-08-16
AU708811B2 (en) 1999-08-12
CN1070498C (en) 2001-09-05
KR100457755B1 (en) 2005-02-28
HUP9802930A1 (en) 1999-04-28
RO120137B1 (en) 2005-09-30
FR2738571A1 (en) 1997-03-14
ZA966837B (en) 1997-08-13
US5969161A (en) 1999-10-19
HK1041489B (en) 2006-09-08
EA199800288A1 (en) 1998-08-27
SI0854880T1 (en) 2004-12-31
HUP9802930A3 (en) 1999-12-28
SK285853B6 (en) 2007-09-06
CA2228670C (en) 2005-04-12
HK1041489A1 (en) 2002-07-12
IL123550A0 (en) 1998-10-30
EP0854880B1 (en) 2004-05-06
EP0854880A1 (en) 1998-07-29
WO1997010251A1 (en) 1997-03-20
NO312678B1 (en) 2002-06-17
PT854880E (en) 2004-09-30
PL183652B1 (en) 2002-06-28
ATE266035T1 (en) 2004-05-15
BG63822B1 (en) 2003-02-28
UA53628C2 (en) 2003-02-17
CZ289945B6 (en) 2002-04-17

Similar Documents

Publication Publication Date Title
AP887A (en) Novel 5-0-deoaminyl 6-0-methyl erythronolide a derivatives method for preparing same application thereof for preparing biologically active products.
Baker et al. Modification of macrolide antibiotics. Synthesis of 11-deoxy-11-(carboxyamino)-6-O-methylerythromycin A 11, 12-(cyclic esters) via an intramolecular Michael reaction of O-carbamates with an. alpha.,. beta.-unsaturated ketone
RU2230748C2 (en) Method for preparing clarithromycin as crystals of form ii
EP0109253A2 (en) Epimeric azahomoerythromycin A derivative and intermediates therefor
EP0496160B1 (en) Synthetic conversion of bryostatin 2 into bryostatin 1
HUP0004085A2 (en) New 3,6-hemiketal derivatives belonging to the group of 9a-azalides
HU193157B (en) Process for preparing 4"-epi-erythromycin a and derivatives thereof
EP0201166B1 (en) Erythromycin derivatives
EP0245013A1 (en) Erythromycin derivatives
EP0097925B1 (en) Tylosin derivatives, processes for their production and pharmaceutical compositions containing them
JP2004536075A (en) Arylation method for functionalizing O-allyl erythromycin derivatives
EP1117671A2 (en) Synthetic method for the preparation of the antineoplastic agent etoposide
EP0627443A1 (en) 3,4'-dideoxymycaminosyltylonolide derivative and production thereof
EP0087915B1 (en) Semi-synthetic oleandomycins and erythromycins
El Khadem et al. Synthesis of 3-amino-2, 3, 6-trideoxy-d-ribo-and-l-lyxo-hexofuranoses suitable for nucleoside synthesis
US20050159371A1 (en) Process for producing erythromycin a derivative
AU2002357482B2 (en) Method for the production of desclarithromycin, and intermediate products
SE445556B (en) NEW 3 "ACYLATED MACROLID ANTIBIOTICS
CA1128506A (en) Semi-synthetic 4"-erythromycin a derivatives
KR820001219B1 (en) Method for preparing semisynthetic 4 "-erythromycin A derivative
WO2005021567A1 (en) O-alkyl macrolide and azalide derivatives and regioselective process for their preparation
JPH11116592A (en) 4"-substituted erythromycin a derivative
HU211493A9 (en) Derivatives 10, 11, 12, 13-tetrahydrodesmycosin, processes for preparation and use thereof in pharmaceuticals
KR20010100197A (en) Process for producing clarithromycin using erythromycin a 9-o-tropyloxime derivatives